Suppr超能文献

阿尔茨海默病:诊断、治疗、护理和预防标准。

Alzheimer Disease: Standard of Diagnosis, Treatment, Care, and Prevention.

机构信息

Department of Psychosomatic Medicine, University Medical Center Rostock, Rostock, Germany;

Deutsches Zentrum für Neurodegenerative Erkrankungen, Rostock/Greifswald, Rostock, Germany.

出版信息

J Nucl Med. 2022 Jul;63(7):981-985. doi: 10.2967/jnumed.121.262239. Epub 2022 Feb 10.

Abstract

Alzheimer disease (AD) is the most frequent cause of dementia in people 60 y old or older. This white paper summarizes the current standards of AD diagnosis, treatment, care, and prevention. Cerebrospinal fluid and PET measures of cerebral amyloidosis and tauopathy allow the diagnosis of AD even before dementia (prodromal stage) and provide endpoints for treatments aimed at slowing the AD course. Licensed pharmacologic symptomatic drugs enhance cholinergic pathways and moderate excess of glutamatergic transmission to stabilize cognition. Disease-modifying experimental drugs moderate or remove brain amyloidosis, but so far with modest clinical effects. Nonpharmacologic interventions and a healthy lifestyle (diet, socioaffective inclusion, cognitive stimulation, physical exercise, and others) provide some beneficial effects. Prevention targets mainly modifiable dementia risk factors such as unhealthy lifestyle, cardiovascular-metabolic and sleep-wake cycle abnormalities, and mental disorders. A major challenge for the future is telemonitoring in the real world of these modifiable risk factors.

摘要

阿尔茨海默病(AD)是 60 岁及以上人群中最常见的痴呆症病因。本白皮书总结了 AD 的诊断、治疗、护理和预防的当前标准。脑脊液和正电子发射断层扫描(PET)测量脑淀粉样蛋白和tau 病可在痴呆(前驱期)之前诊断 AD,并为旨在减缓 AD 病程的治疗提供终点。已批准的药物治疗可增强胆碱能通路并适度减轻谷氨酸能传递过度,从而稳定认知功能。疾病修饰性实验药物可减轻或清除脑淀粉样蛋白,但到目前为止,临床效果有限。非药物干预和健康的生活方式(饮食、社会情感包容、认知刺激、体育锻炼等)提供了一些有益的效果。预防的主要目标是针对可改变的痴呆风险因素,如不健康的生活方式、心血管代谢和睡眠-觉醒周期异常以及精神障碍。未来的一个主要挑战是在现实世界中对这些可改变的风险因素进行远程监测。

相似文献

4
Preventing cognitive decline in preclinical Alzheimer's disease.预防临床前阿尔茨海默病患者认知能力下降。
Curr Opin Pharmacol. 2014 Feb;14:18-22. doi: 10.1016/j.coph.2013.10.002. Epub 2013 Nov 13.
7
8
Souvenaid for Alzheimer's disease.用于治疗阿尔茨海默病的苏威艾迪。
Cochrane Database Syst Rev. 2020 Dec 15;12(12):CD011679. doi: 10.1002/14651858.CD011679.pub2.

引用本文的文献

4
Recent developments in translational imaging of in vivo gene therapy outcomes.体内基因治疗效果的转化成像最新进展。
Mol Ther. 2025 Jun 4;33(6):2548-2564. doi: 10.1016/j.ymthe.2024.12.049. Epub 2024 Dec 30.

本文引用的文献

2
Donanemab in Early Alzheimer's Disease.多奈单抗用于早期阿尔茨海默病
N Engl J Med. 2021 May 6;384(18):1691-1704. doi: 10.1056/NEJMoa2100708. Epub 2021 Mar 13.

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验